IP waiver will not boost vaccine production: OPPI

The Organisation of Pharmaceutical Producers of India (OPPI) on Monday said waiving intellectual property rights will not lead to increased production of COVID-19 vaccines, as it is not the barrier to their adequate availability in India.

A proposal moved by India and South Africa before the World Trade Organisation (WTO) to temporarily suspend trade-related aspects of intellectual property rights for the COVID-19 vaccines to increase their access amid the pandemic has gained support across a number of countries, including the U.S.

Vaccine manufacturing is a complex process and scaling up capacities involves the transfer of critical know-how, it added.

This can only be optimally achieved when vaccine manufacturers are able to scale up capacities at their production sites and/or through licensing agreements with other manufacturers, along with supply agreements with governments to make required quantities deployed rapidly and reliably, OPPI said.

Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Jun 21, 2021 4:26:36 AM |

Next Story